article thumbnail

Ginkgo Bioworks awarded DARPA contract for therapeutic proteins 

Drug Discovery World

The Defense Advanced Research Projects Agency (DARPA) has announced that Ginkgo Bioworks, which is building a platform for cell programming and biosecurity, has been awarded a four-year contract worth up to $18 million to reimagine how to manufacture complex therapeutic proteins.

Protein 52
article thumbnail

Recurrent brain trauma may increase Alzheimer's risk

Medical Xpress

New research finds that the brains of otherwise healthy military personnel who are exposed to explosions show an abnormal brain accumulation of amyloid-beta protein—a protein that plays a role in the development of Alzheimer's disease. The results of the study were published today in Radiology.

Radiology 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Small glowing protein allows researchers to peer deeper into living tissues

Medical Xpress

Biomedical and genetic engineers at Duke University and the Albert Einstein College of Medicine have designed a small fluorescent protein that emits and absorbs light that penetrates deep into biological tissue.

Protein 75
article thumbnail

FDA Approves First Over-the-Counter Fully At-Home Test for COVID-19

The Pharma Data

The new Ellume COVID-19 Home Test approved Tuesday detects severe acute respiratory syndrome coronavirus 2 virus protein fragments on nasal swab samples from any person 2 years of age or older, according to the FDA. Last week, the FDA approved a different at-home test, but it requires samples to be mailed to a lab to get the results.

article thumbnail

Mathematical model can speed up Alzheimer’s drug development

Drug Discovery World

Mapping individual Alzheimer’s disease progression The team’s model relies on clinical biomarkers for Alzheimer’s disease, including fluid markers for the amyloid protein that is responsible for plaque build-up in the brain, cognitive decline scores from pencil-and-paper testing, and MRI brain images.

article thumbnail

AZD1222 US Phase III primary analysis confirms safety and efficacy

The Pharma Data

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. The Phase III D8110C00001 trial is part of this funding agreement. JPEO-CBRND.

article thumbnail

AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis

The Pharma Data

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. The Phase III D8110C00001 trial is part of this funding agreement. JPEO-CBRND.

Trials 52